miR-345 in metastatic colorectal cancer: A non-invasive biomarker for clinical outcome in Non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Schou, Jakob V ^a   Rossi, Simona ^b   Jensen, Benny V ^a   Nielsen, Dorte L ^a   Pfeiffer, Per ^c   Hgødall, Estrid ^a   Yilmaz, Mette ^e   Tejpar, Sabine ^d   Delorenzi, Mauro ^b,g   Kruhføfer, Mogens ^f   Johansen, Julia S ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

^f AROS Applied Biotechnology   (Denmark)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FLUOROURACIL; IRINOTECAN; MICRORNA; MICRORNA 143; MICRORNA 324 3P; MICRORNA 345; MICRORNA 34A; MICRORNA 628 5P; MICRORNA 886 3P; OXALIPLATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; MIRN345 MICRORNA, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER RESISTANCE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENDER; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MUTANT; ONCOGENE K RAS; OVERALL SURVIVAL; PI3KCA GENE; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84903289147     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099886     Document Type: Article

References (48)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer Statistics, 2012. Ca Cancer J Clin 62: 10-29.
2. Van Cutsem E, Nordlinger B, Adam R, Kohne Ch, Pozzo C, et al. (2006) Towards A Pan-European Consensus On The Treatment Of Patients With Colorectal Liver Metastases. Eur J Cancer 42: 2212-2221. (Pubitemid 44307626)
3. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, et al. (2004) Cetuximab Monotherapy And Cetuximab Plus Irinotecan In Irinotecan-Refractory Metastatic Colorectal Cancer. N Engl J Med 351: 337-345. (Pubitemid 38944402)
4. Saltz Lb, Meropol Nj, Loehrer Pj Sr, Needle Mn, Kopit J, et al. (2004) Phase Ii Trial Of Cetuximab In Patients With Refractory Colorectal Cancer That Expresses The Epidermal Growth Factor Receptor. J Clin Oncol 22: 1201-1208.
5. Mirbase Http://Www.Mirbase.Org/Index.Shtml. Accessed 2013.
6. Zhang L, Huang J, Yang N, Greshock J, Megraw Ms, et al. (2006) Micrornas Exhibit High Frequency Genomic Alterations In Human Cancer. Proc Natl Acad Sci U S A 103: 9136-9141. (Pubitemid 43902545)
7. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization Of Micrornas In Serum: A Novel Class Of Biomarkers For Diagnosis Of Cancer And Other Diseases. Cell Res 18: 997-1006.
8. Mitchell Ps, Parkin Rk, Kroh Em, Fritz Br, Wyman Sk, et al. (2008) Circulating Micrornas As Stable Blood-Based Markers For Cancer Detection. Proc Natl Acad Sci U S A 105: 10513-10518.
9. Ng Ek, Chong Ww, Jin H, Lam Ek, Shin Vy, et al. (2009) Differential Expression Of Micrornas In Plasma Of Patients With Colorectal Cancer: A Potential Marker For Colorectal Cancer Screening. Gut 58: 1375-1381.
10. Pu Xx, Huang Gl, Guo Hq, Guo Cc, Li H, et al. (2010) Circulating Mir-221 Directly Amplified From Plasma Is A Potential Diagnostic And Prognostic Marker Of Colorectal Cancer And Is Correlated With P53 Expression. J Gastroenterol Hepatol 25: 1674-1680.
11. Huang Z, Huang D, Ni S, Peng Z, Sheng W, et al. (2010) Plasma Micrornas Are Promising Novel Biomarkers For Early Detection Of Colorectal Cancer. Int J Cancer 127: 118-126.
12. Cheng H, Zhang L, Cogdell De, Zheng H, Schetter Aj, et al. (2011) Circulating Plasma Mir-141 Is A Novel Biomarker For Metastatic Colon Cancer And Predicts Poor Prognosis. Plos One 6: E17745.
13. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, et al. (2013) Serum Mir-21 As A Diagnostic And Prognostic Biomarker In Colorectal Cancer. J Natl Cancer Inst 105: 849-859.
14. Jensen Bv, Schou JV, Johannesen HH, Christensen IJ, Nielsen JS, et al. (2010) Cetuximab Every Second Week With Irinotecan In Patients With Metastatic Colorectal Cancer Refractory To 5-Fu, Oxaliplatin, And Irinotecan: Kras Mutation Status And Efficacy. J Clin Oncol 28, Supplement: Abstract Number 3573.
15. J C (2008) Dxs Ltd. Pharmacogenomics 9: 463-467.
16. Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, et al. (2009) Targeted Kras Mutation Assessment On Patient Tumor Histologic Material In Real Time Diagnostics. Plos One 4: E7746.
17. Richman Sd, Seymour Mt, Chambers P, Elliott F, Daly Cl, et al. (2009) Kras And Braf Mutations In Advanced Colorectal Cancer Are Associated With Poor Prognosis But Do Not Preclude Benefit From Oxaliplatin Or Irinotecan: Results From The Mrc Focus Trial. J Clin Oncol 27: 5931-5937.
18. Kruhoffer M, Dyrskjot L, Voss T, Lindberg Rl, Wyrich R, et al. (2007) Isolation Of Microarray-Grade Total Rna, Microrna, And Dna From A Single Paxgene Blood Rna Tube. J Mol Diagn 9: 452-458. (Pubitemid 47434111)
19. D'haene B, Mestdagh P, Hellemans J, Vandesompele J (2012) miRNA Expression Profiling: From Reference Genes To Global Mean Normalization. Methods Mol Biol 822: 261-272.
20. Willems E, Leyns L, Vandesompele J (2008) Standardization Of Real-Time Pcr Gene Expression Data From Independent Biological Replicates. Anal Biochem 379: 127-129.
21. Johnson We, Li C, Rabinovic A (2007) Adjusting Batch Effects In Microarray Expression Data Using Empirical Bayes Methods. Biostatistics 8: 118-127.
22. Bioconductor Http://Www.Bioconductor.Org/Packages/Release/Bioc/Html/Sva. Html. Accessed 2013.
23. Papadopoulos Gl, Alexiou P, Maragkakis M, Reczko M, Hatzigeorgiou Ag (2009) Diana-Mirpath: Integrating Human And Mouse Micrornas In Pathways. Bioinformatics 25: 1991-1993.
24. Karapetis Cs, Khambata-Ford S, Jonker Dj, O'callaghan Cj, Tu D, et al. (2008) K-Ras Mutations And Benefit From Cetuximab In Advanced Colorectal Cancer. N Engl J Med 359: 1757-1765.
25. Van Cutsem E, Kohne Ch, Hitre E, Zaluski J, Chang Chien Cr, et al. (2009) Cetuximab And Chemotherapy As Initial Treatment For Metastatic Colorectal Cancer. N Engl J Med 360: 1408-1417.
26. Bokemeyer C, Bondarenko I, Makhson A, Hartmann Jt, Aparicio J, et al. (2009) Fluorouracil, Leucovorin, And Oxaliplatin With And Without Cetuximab In The First-Line Treatment Of Metastatic Colorectal Cancer. J Clin Oncol 27: 663-671.
27. Tveit Km, Guren T, Glimelius B, Pfeiffer P, Sorbye H, et al. (2012) Phase Iii Trial Of Cetuximab With Continuous Or Intermittent Fluorouracil, Leucovorin, And Oxaliplatin (Nordic Flox) Versus Flox Alone In First-Line Treatment Of Metastatic Colorectal Cancer: The Nordic-Vii Study. J Clin Oncol 30: 1755-1762.
28. Madi A, Fisher D, Wilson Rh, Adams Ra, Meade Am, et al. (2012) Oxaliplatin/Capecitabine Vs Oxaliplatin/Infusional 5-Fu In Advanced Colorectal Cancer: The Mrc Coin Trial. Br J Cancer 107: 1037-1043.
29. Tang Jt, Wang Jl, Du W, Hong J, Zhao Sl, et al. (2011) Microrna 345, A Methylation-Sensitive Microrna Is Involved In Cell Proliferation And Invasion In Human Colorectal Cancer. Carcinogenesis 32: 1207-1215.
30. Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, et al. (2013) The Shaping And Functional Consequences Of The Microrna Landscape In Breast Cancer. Nature 497: 378-382.
31. Boeri M, Verri C, Conte D, Roz L, Modena P, et al. (2011) Microrna Signatures In Tissues And Plasma Predict Development And Prognosis Of Computed Tomography Detected Lung Cancer. Proc Natl Acad Sci U S A 108: 3713-3718.
32. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, et al. (2007) Altered Expression Of Mir-21, Mir-31, Mir-143 And Mir-145 Is Related To Clinicopathologic Features Of Colorectal Cancer. Oncology 72: 397-402. (Pubitemid 351238155)
33. Kulda V, Pesta M, Topolcan O, Liska V, Treska V, et al. (2010) Relevance Of Mir-21 And Mir-143 Expression In Tissue Samples Of Colorectal Carcinoma And Its Liver Metastases. Cancer Genet Cytogenet 200: 154-160.
34. Arndt Gm, Dossey L, Cullen Lm, Lai A, Druker R, et al. (2009) Characterization Of Global Microrna Expression Reveals Oncogenic Potential Of Mir-145 In Metastatic Colorectal Cancer. Bmc Cancer 9: 374.
35. Chen X, Guo X, Zhang H, Xiang Y, Chen J, et al. (2009) Role Of Mir-143 Targeting Kras In Colorectal Tumorigenesis. Oncogene 28: 1385-1392.
36. Pichler M, Winter E, Stotz M, Eberhard K, Samonigg H, et al. (2012) Down-Regulation Of Kras-Interacting miRNA-143 Predicts Poor Prognosis But Not Response To Egfr-Targeted Agents In Colorectal Cancer. Br J Cancer 106: 1826-1832.
37. Nugent M, Miller N, Kerin Mj (2012) Circulating Mir-34a Levels Are Reduced In Colorectal Cancer. J Surg Oncol 106: 947-952.
38. Hu Z, Dong J, Wang Le, Ma H, Liu J, et al. (2012) Serum Microrna Profiling And Breast Cancer Risk: The Use Of Mir-484/191 As Endogenous Controls. Carcinogenesis 33: 828-834.
39. Luo X, Stock C, Burwinkel B, Brenner H (2013) Identification And Evaluation Of Plasma Micrornas For Early Detection Of Colorectal Cancer. Plos One 8: E62880.
40. Hofsli E, Sjursen W, Prestvik Ws, Johansen J, Rye M, et al. (2013) Identification Of Serum Microrna Profiles In Colon Cancer. Br J Cancer 108: 1712-1719.
41. Patnaik Sk, Yendamuri S, Kannisto E, Kucharczuk Jc, Singhal S, et al. (2012) Microrna Expression Profiles Of Whole Blood In Lung Adenocarcinoma. Plos One 7: E46045.
42. Schultz Na, Dehlendorff C, Jensen Bv, Bjerregaard Jk, Nielsen Kr, et al. (2014) Microrna Biomarkers In Whole Blood For Detection Of Pancreatic Cancer. Jama 311: 392-404.
43. Heneghan Hm, Miller N, Kerin Mj (2010) Circulating miRNA Signatures: Promising Prognostic Tools For Cancer. J Clin Oncol 28: E573-574; Author Reply E575-576
44. Cheng Hh, Yi Hs, Kim Y, Kroh Em, Chien Jw, et al. (2013) Plasma Processing Conditions Substantially Influence Circulating Microrna Biomarker Levels. Plos One 8: E64795.
45. Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization Of Extracellular Circulating Microrna. Nucleic Acids Res 39: 7223-7233.
46. Vickers Kc, Palmisano Bt, Shoucri Bm, Shamburek Rd, Remaley At (2011) Micrornas Are Transported In Plasma And Delivered To Recipient Cells By High-Density Lipoproteins. Nat Cell Biol 13: 423-433.
47. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, et al. (2010) Secretory Mechanisms And Intercellular Transfer Of Micrornas In Living Cells. J Biol Chem 285: 17442-17452.
48. Shen J, Xia W, Khotskaya Yb, Huo L, Nakanishi K, et al. (2013) Egfr Modulates Microrna Maturation In Response To Hypoxia Through Phosphorylation Of Ago2. Nature 497: 383-387.